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Abstract
Aims/hypothesis In this study we examined the cost-effectiveness of three different screening strategies for diabetic retinopathy:
using a personalised adaptive model, annual screening (fixed intervals), and the current Dutch guideline (stratified based on
previous retinopathy grade).
Methods For each individual, optimal diabetic retinopathy screening intervals were determined, using a validated risk prediction
model. Observational data (1998–2017) from the Hoorn Diabetes Care System cohort of people with type 2 diabetes were used
(n = 5514). The missing values of retinopathy grades were imputed using two scenarios of slow and fast sight-threatening
retinopathy (STR) progression. By comparing the model-based screening intervals to observed time to develop STR, the number
of delayed STR diagnoses was determined. Costs were calculated using the healthcare perspective and the societal perspective.
Finally, outcomes and costs were compared for the different screening strategies.
Results For the fast STR progression scenario, personalised screening resulted in 11.6%more delayed STR diagnoses and €11.4
less costs per patient compared to annual screening from a healthcare perspective. The personalised screening model performed
better in terms of timely diagnosis of STR (8.8% less delayed STR diagnosis) but it was slightly more expensive (€1.8 per patient
from a healthcare perspective) than the Dutch guideline strategy.
Conclusions/interpretation The personalised diabetic retinopathy screening model is more cost-effective than the Dutch guide-
line screening strategy. Although the personalised screening strategy was less effective, in terms of timely diagnosis of STR
patients, than annual screening, the number of delayed STR diagnoses is low and the cost saving is considerable.With around one
million people with type 2 diabetes in the Netherlands, implementing this personalised model could save €11.4 million per year
compared with annual screening, at the cost of 658 delayed STR diagnoses with a maximum delayed time to diagnosis of
48 months.
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Diabetic retinopathy is the leading cause of vision impairment and
new-onset blindness in many countries [1–3]. It has been estimat-
ed that the global prevalence of diabetes among adults will
increase from 8.4% in 2017 to 9.9% in 2045 (from 451 million
to 693 million people, age 18–99 years) [4]. Hence, more people
may be affected by diabetic retinopathy. In the Netherlands, the
population with diabetes was estimated at 1.1 million, of which
90% had type 2 diabetes [5], and around 10–15% of all people
with diabetes had diabetic retinopathy [6]. Since detecting diabetic
retinopathy in early stages can prevent severe irreversible damage
[7], screening for diabetic retinopathy in people with diabetes is
vital. Therefore, in many countries, either annual or biennial
(every 2 years) screening is recommended [8, 9]. Such screening
serves to refer individuals with diabetic retinopathy to secondary
care in time to prevent or limit such severe damage.
Internationally, guidelines vary in the level of retinopathy indicat-
ed for a referral to an ophthalmologist for immediate treatment or
careful follow-up. In the current Dutch guidelines, as in the UK,
the EURODIAB grade 3 (UK R2 level; sometimes also referred
to as sight-threatening retinopathy [STR]) is considered an appro-
priate level for referral [6].
However, not all people with diabetic retinopathy develop
STR. In those that do develop STR, a latent stage of diabetic
retinopathy, symptoms are clearer and have a significant impact
on patients’ quality of life [10, 11], and usually require active
treatment. Notably, the risk of developing STR is highly variable
and ‘one size fits all’ approaches may therefore not only lead to
late screening in high-risk patients, but also over-screening in low-
risk patients [12, 13]. Moreover, from a health economics
perspective, ‘one size fits all’ approaches will pose unnecessary
costs for both healthcare systems and patients.
In previous cost-effectiveness analyses of diabetic retinopathy
screening, different screening algorithms have been explored.
Some algorithms assumed variable screening intervals by strati-
fying patients varying from 6 months up to 5 years [14, 15]. A
recent review of diabetic retinopathy prediction models showed
the models by Scanlon et al [15] and Aspelund et al [12]
performed better than other models [16]. Scanlon et al developed
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a personalised risk profile in which the screening intervals varied
from 6months to 5 years; the cost-effectiveness of this model has
been previously assessed [15]. Aspelund et al proposed a model
to compute personalised screening intervals based on individual
patient characteristics [12]. This model was validated in different
cohorts, including the cohort used in the present study, showing
good model performance [13, 16–18]. Nevertheless, the cost-
effectiveness of this screening strategy has not been assessed. In
the Dutch guideline, renewed in 2016, a stratified approach with
screening intervals ranging from 1 to 3 years was advised, based
on previous presence of retinopathy. In the present study we
aimed to assess the cost-effectiveness of a personalised screening
interval based on estimated diabetic retinopathy risk using the
Aspelundmodel comparedwith screening strategies using a fixed
interval (annual screening) and a stratified approach based on
previous retinopathy grades (Dutch guideline).
Methods
Study design We performed a cost-effectiveness study based
on routine care data. After optimising the personalised strate-
gy by setting its risk margin, results for personalised and
Dutch guideline screening strategies were compared with
annual screening in terms of differences in costs and the
number of delayed STR diagnoses. Then, a comparison
between the personalised and Dutch guideline screening strat-
egies was performed.
Study population To study the impact of different diabetic
retinopathy screening intervals on development of STR, we
used the Hoorn Diabetes Care System (DCS) cohort, a
dynamic primary care cohort of people with type 2 diabetes
in the Netherlands [19]. Data were available over the period
from the beginning of 1998 up to the end of 2017. There were
13,959 people in the total cohort, with a varying date of entry
and exit, resulting in patient follow-up varying between 0 and
18 years. Inclusion criteria for the current study were: (1) at
least one measurement of a grade of retinopathy available; (2)
having no STR at baseline; and (3) at least 5 years of follow-
up available. The latter criterion was based on the maximal
screening interval that the Aspelund et al model would predict,
i.e. 5 years [12]. For all participants, we used patient-level
results from all routine clinical and laboratory measurements
that were available. The measurements in the cohort included,
but were not limited to, systolic BP (SBP), diastolic BP,
HbA1c, BMI, cholesterol level and triacylglycerol, date of
diagnosis of type 2 diabetes, ethnic group, and fundus photog-
raphy including retinopathy grades. The retinopathy grades
were reported according to the EURODIAB scale, which
ranges from 0 to 5 [20]: grade 0 means no retinopathy; grade
1 is ‘minimal non-proliferative retinopathy’; grade 2 is
‘moderate non-proliferative retinopathy’; grade 3 is ‘severe
non-proliferative retinopathy’; grade 4 is ‘photocoagulated
retinopathy’; and grade 5 is ‘proliferative retinopathy’.
According to the Dutch guideline, grades 3–5 were considered
STR, and usually, patients with these grades were referred to
an ophthalmologist for treatment [13, 16]. The study has been
approved by the Medical Ethical Review Committee of the
VU University Medical Center, Amsterdam. Individuals were
informed about the use of their data and were offered an opt-
out. Data were used anonymously.
Imputation for missing values Missing explanatory variables
(duration of diabetes, HbA1c and SBP) were imputed by the
mean value conditional on retinopathy grade. For missing
values of the dependent variable of retinopathy grade, a differ-
ent approach was followed. First, we used information from
adjacent measurements in the same individual for interpola-
tion, and if the grades before and after the missing value were
the same, we filled out the missing value with that grade. If
grades differed, a uniform distribution between the two adja-
cent grades was assumed, and a random draw from this distri-
bution was applied and rounded to an integer value. Second,
for patients with STR missing the time to develop STR, two
extreme scenarios were used to reflect a broad range of possi-
ble outcomes, i.e. slow and fast STR progression assumptions.
In the slow STR progression assumption, STR was assumed
to have developed at the last possible time point. In the fast
STR progression assumption, STR was assumed to have
developed at the first possible time point. Fast STR progres-
sion was taken as a base assumption for imputation and slow
STR progression assumption used for sensitivity analysis.
Duration of diabetes, HbA1c and SBP were missing for
1.0%, 1.7% and 2.0%, respectively, of all records.
Retinopathy grades of participants without STR showed
12.2% missing values over all the records. Of these, 10.1%
had the same grades before and after the missing value, while
for the remaining 2.1%, grades differed. For 22% of partici-
pants with STR, some retinopathy grades were missing, and
needed to be imputed.
Data analysis In order to perform cost-effectiveness analysis,
first, we needed to optimise the screening model [12] to deter-
mine the personalised diabetic retinopathy screening strategy.
To do so, a preset risk margin (i.e. the risk of developing STR
given a certain screening interval) was assumed.
Subsequently, different intervals using a personalised diabetic
retinopathy screening model were simulated, and the clinical
outcomes and costs of these screening intervals were
calculated.
Determining personalised screening intervals To estimate
personalised screening intervals, we used the model previous-
ly developed by Aspelund et al [12]. A brief description of
Aspelund’s model is provided in electronic supplementary
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material (ESM) Methods. In short, this model predicts the
time to develop STR based on individual patient characteris-
tics which include mean blood glucose or HbA1c, SBP, pres-
ence of retinopathy, sex, and duration of diabetes. In the orig-
inal publication, the personalised intervals for screening using
Aspelund’s model were determined based on a preset fixed
risk margin of 3.2%. This risk margin was derived from the
proportion of people that developed STR in their first year of
the screening programme in the original dataset used by
Aspelund et al [12], and basically reflected patients’ current
real-world STR risk. Of note, in our analysis, we varied this
risk margin between 0.0% and 4.0% and applied the corre-
sponding personalised screening interval in our simulation.
Before comparisonwith the other two strategies, we optimised
the risk margin from the perspective of costs per case of
delayed diagnosis, as explained below.
One to 3 year screening interval recommended by the Dutch
guideline In the Dutch diabetic retinopathy guideline, people
with diabetes are divided into two subgroups: those without
previously known retinopathy and those already having a low
retinopathy grade at baseline. The recommended diabetic reti-
nopathy screening intervals are based on the retinopathy
grade. If the individual does not have retinopathy at the first
visit, then the next screening visit is after 2 years. If after
2 years still no retinopathy is present, the screening interval
is increased to 3 years. If the individual has mild retinopathy
(grades 1–2), then the screening interval will be annual, and in
severe cases (grades 3–5) patients should be referred to an
ophthalmologist [6].
Clinical outcomes The clinical outcome was the number of
delayed STR diagnoses. This was calculated by counting the
number of patients for whom the personalised screening
model that was simulated predicted longer intervals than the
observed time to STR diagnosis (based on the real-world
longitudinal DCS cohort follow-up). In the present study, we
did not consider quality-adjusted life years (QALYs) as an
outcome since an estimate of QALYs would require elaborate
modelling which would introduce more uncertainty in the
study.
Costs We considered the healthcare perspective for the main
cost analysis, while we added productivity losses and travel
costs in a sensitivity analysis. Discount rates of 1.5% and
4.0% were applied to effects and costs, respectively, in line
with Dutch health economic guideline recommendations [21].
We did not include treatment costs, since all patients with
retinopathy will eventually be treated in each of the three
different strategies, with only slight differences in the timing
of treatment. Price levels used were for 2015.
For the maximum screening costs, the tariff of a large
Dutch commercial laboratory was used [22]. For the
minimum screening costs, a calculation based on micro-
costing was applied [23]. Screening costs ranged from
€15.25 to €41.07. Travel costs ranged from €1.58 to €14.19
[23]. Productivity losses were estimated to vary from €2.63 to
€16.62 [24]. For all cost types, a gamma distributionwas fitted
to the minimum and maximum cost estimates to reflect the
uncertainty. The details of costs are shown in ESM Table 1.
Determination of the best risk margin for personalised
screening To determine the best risk margin for use with the
Aspelundmodel, risk margins were varied from 0 to 4, and for
each risk margin the savings per case with a delayed STR
diagnosis were assessed using a stepwise approach. For each
0.1% increase in the risk margin, we calculated the incremen-
tal cost saving and compared these to the additional delayed
STR diagnoses. The incremental cost saving per delayed STR
diagnosis was computed as the ratio of differences in costs to
differences in delayed STR diagnoses for each risk margin as
compared with the previous risk margin. The best risk margin
was considered to be the one with the lowest number of
delayed STR cases at which incremental savings per delayed
STR case would peak.
Sensitivity analysis In order to capture the uncertainty around
the study sample and around the costs of screening, we
conducted bootstrapping (1000 simulations) from the study
sample and varied costs over their full ranges.
Bootstrapping with 1000 simulations was performed for
the fast and slow progression assumptions. In the first step,
the best risk margin in each iteration was determined. Then,
for the mean over the iterations of the best risk margin, prob-
abilistic sensitivity analysis using different cost estimates for
healthcare perspective (screening cost) and societal perspec-
tive (travel cost and productivity loss) was conducted with
1000 iterations, again varying the sample using bootstrapping
techniques, but now also varying the costs.
All analyses were performed with the statistical software
package R (version 3.6.1) (www.rproject.org) [25] in
combination with Microsoft Excel 2010 for Windows.
Results
Study population selection and characteristics In the DCS
cohort, at least one grade of retinopathy was available for
12,791 people with diabetes. Among these, 122 patients had
STR (grade 3, 4 or 5) at baseline and were excluded. Figure 1
shows the flow chart of participant selection and how many
were excluded in each step.
Study population characteristics are shown in Table 1 by
retinopathy grade at baseline. On average, as the retinopathy
grade increased, the levels of SBP, HbA1c and duration of
diabetes at baseline also increased.
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Number of delayed STR diagnoses for different risk margins
Figure 2 shows the percentage of delayed STR diagnoses
based on the fast STR progression assumptions at different
risk margins. Using the fast STR progression assumption,
the number of delayed STR diagnoses varied from 0 (0.0%)
to 35 (0.63%). The number of delayed STR diagnoses in the
slow STR progression assumption is shown in ESM Fig. 1.
Determining the best risk margin Figure 3 shows the total
absolute cost of personalised screening (per patient) from a
healthcare perspective. The cost started at €27 for a risk
margin of 0.0% and decreased to €4 per patient per year for
a risk margin of 4.0%. Very low risk margins implied more
frequent screening, and hence as the risk margin increased,
costs started to decline, but the number of delayed STR
diagnoses rose (Fig. 2). Screening costs seemed to reach a
plateau, which implies that, once high, increasing riskmargins
do not continue to bring many extra savings.
Figure 4 combines Figs 2 and 3 and shows the incremental
cost saving per delayed STR diagnosis, compared with a
slightly lower risk margin from the healthcare perspective. It
is important to note that increasing the risk margin decreased
costs but increased the number of delayed STR diagnoses.
The risk margin that maximised the incremental saving per
delayed STR diagnosis for the slow progression assumption
was the same as for the fast progression assumption and was
2.0% (ESM Fig. 2). The mean screening intervals started at
6.0 months and increased to 31.7 months for risk margins
between 0.0% and 4.0%. The mean screening intervals and
the number of delayed STR diagnoses for different risk
Total DCS cohort:
N=13,959
Participants with at least 
one grade of retinopathy 
available:
n=12,791





Excluded as retinopathy grade not 
available:
n=1168
Excluded as <5 years of follow-up 
available:
n=7155
Excluded because of STR at 
baseline:
n=122 
Fig. 1 Patient selection flow chart
Table 1 Baseline characteristics
of the study population Characteristic No retinopathy Grade 1 retinopathy Grade 2 retinopathy
Retinopathy grade, n, % 5173 (93.8) 282 (5.1) 59 (1.1)
Age, mean (SD) 60.3 (10.8) 61.2 (10.8) 60.0 (9.9)
Male, % 53.9 54.6 62.7
Diabetes duration, years, median (IQR) 0.8 (0.2–2.9) 2.11 (0.3–7.1) 5.8 (1.5–13.6)
HbA1c, mmol/mol, mean (SD) 55.7 (17.1) 60.9 (19.7) 70.4 (19.4)
HbA1c, %, mean (SD) 7.2 (1.5) 7.7 (1.8) 8.6 (1.8)
SBP, mean (SD) 142.5 (20.1) 145.2 (22.3) 149.1 (20.5)
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margins and the best risk margin are shown in ESM Tables 2
and 3 for the slow and fast progression assumption.
Costs and outcomes of personalised screening compared with
the annual screening and Dutch guideline The DCS cohort
was mostly subject to annual screening as it covered the peri-
od 1998–2017. The personalised screening strategy resulted in
15 to 18 (9.7% to 11.6% of STR cases) delayed STR diagno-
ses, for the slow and fast STR progression assumptions,
respectively. Applying a screening strategy according to the
current Dutch guideline to this cohort would result in a total of
28 to 32 (18.1% to 20.7% of STR cases) delayed STR diag-
noses, which is more than the personalised screening strategy,
for the slow and fast STR progression assumptions, respec-
tively. Figure 5 shows the cost-effectiveness plane of the
personalised screening strategy compared with annual screen-
ing and the Dutch guideline screening strategy compared with
annual screening for fast STR progression from a healthcare
and societal perspective. The corresponding figure for slow
STR progression is shown in ESM Figs 3 and 4. Both the
personalised and the Dutch guideline screening strategy were
less effective regarding delayed STR diagnoses but also less
costly than the annual screening strategy. The Dutch guideline
screening strategy was less effective and less costly than
personalised screening for both fast and slow STR progres-
sion. Assuming fast progression, the median delay for the
Dutch guideline strategy was 12.0 months while for the
personalised model, the median delay was 15.3 months.
Assuming slow STR progression, the median delay for the
Dutch guideline strategy was 12.0 months, while for the
personalised model this was 13.5 months. ESM Tables 3
and 4 show the mean, median and IQR of these delays and
also the baseline grade for delayed STR diagnoses.
Sensitivity analysis The mean of best risk margins were 2.0%
(95% CI 1.3%, 2.9%) and 2.0% (95% CI 1.3%, 3.1%) for the
fast and slow progression assumptions, respectively. Table 2
shows the results of the sensitivity analyses in terms of total
costs, saving per patient per year, incremental cost-
effectiveness ratio, and the number of delayed STR diagnoses
by comparing the personalised and Dutch guideline screening
strategies with the annual screening strategy for a risk margin
of 2.0%with the fast STR progression assumption. The results
for slow STR progression assumption are presented in ESM
Table 5. Both the personalised and the Dutch guideline
screening strategy performed worse in terms of detecting
STR cases on time, but they cost less compared with annual
screening. While on average the personalised screening was
slightly more expensive than the Dutch guideline, it could
detect the STR cases more effectively.
In order to compare different strategies, first the compari-
son of personalised screening and Dutch guideline with the
annual screening was performed. The cost-effectiveness
planes and cost-effectiveness acceptability curves (CEACs)
are shown in ESM Figs 3 and 4 and ESM Fig. 5, respectively.





























Fig. 3 Total absolute costs of
screening for different risk
margins from a healthcare
perspective with the fast STR
progression assumption, mean


























Fig. 2 The percentage of delayed
STR diagnoses for different risk
margins for fast STR progression,
mean over 1000 bootstrap
replications
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personalised screening is higher than the Dutch guideline.
Then the personalised screening was compared with Dutch
guideline (ESM Figs 6, 7). In the CEAC curve the Dutch
guideline had a relatively low probability of being cost-
effective for most threshold values of saving per delayed
STR diagnosis compared with personalised screening (ESM
Fig. 8.)
Discussion
Main findings Personalised screening for retinopathy using a
risk prediction model developed by Aspelund et al and an
optimised risk margin implied an increase of 11% in the
number of delayed STR diagnoses, or a mean delay of
18 months compared with annual screening, resulting in cost
savings of nearly €11 per patient per year from a healthcare
perspective. Compared with the current Dutch guideline, for
fast STR progression, the personalised screening strategy
resulted in around 9% less delayed STR diagnoses, at a slight-
ly higher cost per patient (€1.8), respectively, from a
healthcare perspective. Of note, the mean delay in the
personalised model was about 6 months longer than in the
Dutch guideline algorithm. This delay was due to the larger
maximum screening interval of 5 years, vs 3 years in the
Dutch guideline. When personalised screening intervals were
applied, the mean best risk margin for both assumptions was
2.0%. This risk margin is stricter than the risk margins that
were proposed in the original publications of the risk predic-
tion model.
Interpretation Screening for diabetic retinopathy is one of the
most effective ways of preventing severe and irreversible
complications. Annual screening has been recommended by
WHO and most health institutes [12]. In line with our find-
ings, a publication by Scanlon et al showed that annual screen-
ing is not cost-effective [15]. However, according to a system-
atic review by Taylor-Phillips et al, not enough evidence
existed to show that extending the screening interval to more
than 1 year is safe [26]. Instead of delayed detection of STR
cases, Scanlon et al used QALYs as an outcome, and they
concluded that for patients without retinopathy at baseline,
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Fig. 4 Incremental saving per
delayed STR diagnosis for the fast
STR progression assumption
from a healthcare perspective,
mean over 1000 bootstrap
replications
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strategy [15], while some other studies suggested a 2 to 3 year
screening interval was cost-effective [27–29].
While more favourable from a cost-effectiveness perspec-
tive, a possible limitation of implementing a personalised
model is a reduction in screening attendance, when variable
intervals cause a changed engagement or changed routine.
Within the DCS setting of annual diabetes control visits, with
or without the retinopathy screening embedded, this risk is
probably quite small. However, having variable screening
intervals might have an impact on attendance rate [30].
Our current analysis adds a cost-effectiveness study of
another personalised screening strategy, using the Aspelung
prediction model, and comparing it to both annual screening
and stratified (Dutch guideline) screening. From a clinical,
epidemiological perspective, the original personalised model
of Aspelund et al that was used in our analysis proposed a risk
margin of 3.2%. Based on the ratio of extra savings to the
number of delayed STR diagnoses, our evaluation indicated
that stricter risk margins of 2.0% (95% CI 1.3%, 3.1%)
performed better. This stricter risk margin also reduces the
mean delay in detecting STR cases.
Strengths and limitations The strength of this study is that we
used observational data from routine clinical practice for a
large number of people with type 2 diabetes with longitudinal
follow-up. However, thanks to routine care for people with
diabetes in the Netherlands, the number of STR cases is rela-
tively rare in the cohort. A limitation inherent to the use of
routine care data is the presence of missing values. However,
the proportion of missing values in the predictors was relative-
ly low. Missing annual retinopathy grades, mostly as a result
of clinicians already applying biennial screening intervals,
were more problematic since these were the outcomes rather
than the predictors and they were missing for 22% of the STR
cases, and 2% of the non-STR cases. We addressed this by
investigating a slow and fast STR progression assumption for
STR and by interpolating missing values for non-STR cases.
Findings for the fast STR progression assumption are to be
considered as conservative since missing values were
assumed to have the highest observed retinopathy grade.
The cohort used in this study is a well-controlled diabetes
population with centrally organised care, and checks related to
diabetes risk factors are performed on an annual basis.
Therefore, generalising this model to less well-controlled
diabetes populations should be done with caution. The grade
of retinopathy in each eye was not available in the cohort;
however, it will not have an impact on our analyses because
in the Aspelund et al model, the overall grade is needed.While
a delayed diagnosis will not improve the condition, due to the
different risk factors involved in diabetic retinopathy, it
remains unclear as to how much a delay puts the patients in
danger of irreversible damage or even blindness. On the basis
of experts’ opinions, the consequences of an STR diagnosis
delayed up to 2 years may not have an impact on patients’
conditions. However, we do not know the exact clinical and
economic consequences of late diagnosis, and therefore,
although relevant, these costs were not taken into account.
Similarly, only effects in terms of delayed STR were
compared rather than modelling the effects of delay over a
lifetime horizon which would be needed to estimate QALYs
as an outcome. Such long-term modelling would add more
complexity and uncertainty in the study. Hence, the current
study used delayed STR diagnosis as the health outcome of
interest, instead of QALYs, which is in contrast to a previous
study by Scanlon et al [15]. Costs per case detected late are
sufficient to enable comparison of various screening strategies
for their cost-effectiveness. However, when policymakers
want to compare retinopathy screening to other diabetes treat-
ments or broader healthcare policy, a cost per QALY outcome
is required. Another limitation of this study was that we






Total costs – annual screening, €1000 682 (433, 966) 1018 (721, 1336)
Total costs – personalised screening, €1000 361 (228, 510) 539 (380, 717)
Total costs – Dutch guideline screening, €1000 310 (196, 437) 472 (325, 610)
Saving per patient per year – personalised compared with annual, € 11.4 (7.5, 16.5) 17.2 (12.4, 22.9)
Saving per patient per year – Dutch guideline compared with annual, € 13.2 (8.8, 19.1) 19.9 (14.3, 26.7)
ICER saving per delayed STR diagnosis – personalised compared with annual, €1000 18,844 (10,516, 32,533) 28,137 (16,500, 43,049)
ICER saving per delayed STR diagnosis – Dutch guideline compared with annual, €1000 12 (7, 19) 18 (11, 26)
Number of delayed STR diagnoses – personalised screening (out of 155 STR cases) 18.0 (11.5, 24.9) 18.0 (11.5, 24.9)
Number of delayed STR diagnoses – Dutch guideline screening (out of 155 STR cases) 31.6 (23.0, 41.3) 31.6 (23.0, 41.3)
ICER, incremental cost-effectiveness ratio
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assumed that annual screening did not result in any delayed
detection of STR cases since the minimum screening interval
in the cohort between 1998 and 2013 was 1 year. The
personalised strategy also permits 6 month screening intervals
for the highest risk group and, as such, offers a higher level of
surveillance for these individuals.
Recommendations Although the model proposed by
Aspelund et al performed well on predicting the personalised
diabetic retinopathy screening intervals based on patient risk
factors and reduced total screening costs, still the proportion
of delayed STR diagnoses was relatively high at 11%, indi-
cating room for further improvement of the model. The maxi-
mum screening interval in this model is 5 years, leading to a
median delay of 15.3 months. More knowledge is needed on
the consequences of such delays, and what maximum delay in
detecting STR is acceptable from a clinical point of view. This
knowledge could be used to modify the maximum screening
interval.
In conclusion, a personalised diabetic retinopathy screen-
ing strategy, in a well-controlled diabetes population, led to
cost savings at a loss of health in terms of additional delay in
STR detection for 11% of individuals with STR. At the same
time, it outperformed the stratified approach based on current
retinopathy grade as advocated in the Dutch guidelines. With
around 1 million individuals with diabetes in the Netherlands,
implementing this personalised model could save €11.4
million per year compared with annual screening, at the cost
of 551 to 658 delayed diagnoses of STR.
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